Ibrutinib CAS 936563-96-1 Purity >99.5% (HPLC) API

Tlhaloso e Khutšoanyane:

Lebitso la lik'hemik'hale: Ibrutinib

CAS: 936563-96-1

Bohloeki: >99.5% (HPLC)

Ponahalo: Bosoeu ho isa ho Bosoeu ba Crystal Powder

Ibrutinib ke BTK inhibitor e sebelisetsoang ho phekola Chronic Lymphocytic Leukemia (CLL) le Mantle Cell Lymphoma (MCL)

Ikopanye le: Dr. Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Re romelle lengolo-tsoibila

Lintlha tsa Sehlahisoa

Lihlahisoa tse Amanang

Li-tag tsa Sehlahisoa

Tlhaloso:

Likahare tse Amanang le Ibrutinib:
(S)-1-Boc-3-Hydroxypiperidine CAS 143900-44-1
4-Phenoxyphenylboronic Acid CAS 51067-38-0
Ibrutinib Intermediate N-2 CAS 330786-24-8
Ibrutinib Intermediate N-3 CAS 330792-70-6
Ibrutinib CAS 936563-96-1

Lintho tsa Lik'hemik'hale:

Lebitso la Lik'hemik'hale	Ibrutinib
Litlhaloso tse tšoanang	1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1- ngoe;PCI-32765
Nomoro ea CAS	936563-96-1
Boemo ba Setoko	Ka Setokong, Sekhahla sa Tlhahiso Ho fihlela ho Lithane
Foromo ea limolek'hule	Setšoantšo sa C25H24N6O2
Boima ba Molek'hule	440.50
Brand	Ruifu Chemical

Litlhaloso:

Ntho	Litlhaloso
Ponahalo	Bosoeu ho isa ho bosoeu ba Crystal Powder
Boitsebiso	IR;HPLC
Tahlehelo ka ho Omisa	<0.50%
Masalla a ho Ignition	≤0.10%
Heavy Metals (as Pb)	≤20ppm
Tšilafalo efe kapa efe e le 'Ngoe	≤0.20%
Litšila ka Kakaretso	<0.50%
Mokhoa oa Bohloeki / Analysis	>99.5% (HPLC)
Tekanyetso ea Teko	Maemo a Khoebo
Tšebeliso	API

Sephutheloana le Bobolokelo:

Sephutheloana: Botlolo, Aluminium foil bag, 25kg/Cardboard Drum, kapa ho ea ka tlhokahalo ea moreki.

Boemo ba polokelo:Boloka ka lijaneng tse koetsoeng sebakeng se phodileng le se omileng;Sireletsa leseli le mongobo.

Melemo:

LBH:

Kopo:

Ibrutinib (CAS: 936563-96-1) ke inhibitor ea Bruton tyrosine kinase (BTK) bakeng sa phekolo ea boloetse bo sa foleng ba lymphocytic leukemia (CLL) le mantle cell lymphoma (MCL).Ka bobeli MCL le CLL ke tsa B-cell non-Hodgkin's lymphoma, e hananang le ho khutlela mokhoeng ona hape.Chemoimmunotherapy e atisang ho sebelisoa ha e lebisetsoe, 'me hangata ho hlaha liphetoho tse mpe tsa sehlopha sa 3 kapa sa 4.Ibrutinib e ka kopana le BTK, e hlokahalang bakeng sa ho thehoa, ho khetholla, ho buisana le ho phela ha li-lymphocyte tsa B, le ho thibela mosebetsi oa BTK ka mokhoa o ke keng oa qojoa, ho thibela ka katleho ho ata le ho phela ha lisele tsa hlahala.Ntle le moo, e kenella ka potlako kamora ho tsamaisoa ka molomo, khatello e phahameng ea plasma e fihla ho 1 ~ 2h, mme karabelo e mpe ke grade 1 kapa 2, e tla fetoha khetho e ncha bakeng sa kalafo ea CLL le MCL.Ka la 13 Pulungoana 2013, US FDA ho potlakisa khamphani e amohetsoeng ea Johnson & Johnson le United States Imbruvica (lebitso le tloaelehileng: Ibrutinib) bakeng sa kalafo ea mantle cell lymphoma (MCL).Ibrutinib, e ile ea fuoa boemo ba Therapy ke FDA ka Hlakola 2013 mme ea amoheloa bakeng sa MCL ka la 13 Pulungoana 2013 le CLL ka Hlakola 12, 2014, ka ho latellana.